Shiraj Sen, Medical Oncologist, Director of NEXT Oncology–Dallas, and Principal Investigator of Multiple Early-Phase Clinical Trials, Shared on LinkedIn:
“Thanks to Total Health and Program Chair Salwan Al Mutar for a great Best of American Society of Clinical Oncology (ASCO) Dallas! It was great presenting on the progress we are making for individuals with small cell lung cancer, including emerging data on DLL3- and B7-H3-targeted antibody-drug conjugate (ADC) clinical trials available at NEXT Oncology, an Avacare business.”
Other articles about small cell lung cancer on OncoDaily.